Influenced by an article on the National Post website, this looks deeper into the ethical dilemma surrounding clinical trials when patients have to pay to participate in them.
The industry’s education of genomes has grown, but we must do more to engage and empower health care consumers — the ultimate sources of data. This article looks at what still can be done to make the most of the potential of precision medicine.
One viewpoint on clinical trial transparency and the improvements that have recently been made.
Photo courtesy of Flickr